Bibliography
- BARR SG, ZONANA-NACACH A, MAGDER LS, PETRI M: Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. (1999) 42(12):2682–2688.
- ••A systematic study of diverse clinicalpatterns in SLE.
- Trends in Deaths from Systemic Lupus Erythematosus - United States, 1979-1998 morbidity and mortality weekly report. (2002) 51(17): 371–374.
- STOJANOVICH L, STOJANOVICH R, KOSTICH V, DZJOLICH E: Neuropsychiatric lupus favourable response to low dose Iv. cyclophosphamide and prednisolone (pilot study). Lupus. (2003) 12:10–15.
- ZONANA-NACACH A, BARR SG, MAGDER LS, PETRI M: Damage in systemic lupus and its association with corticosteroids. Arthritis Rheum. (2000) 43:1801–1808.
- FISHER DE, BICKEL WH: Corticosteroid-induced a vascular necrosis. A clinical study of seventy-seven patients. Bone Joint Surg. Am. (1971) 53:859–873.
- BADSHA H, EDWARDS CJ: Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin. Arthritis Rheum. (2003) 32:370–377.
- TAM LS, GLADMAN DD, HALLETT DC, RAHMAN P, UROWITZ MB: Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. Rheumatol (2000) 27:2142–2145.
- BORBA EF, BONFA E: Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J. Rheumatol (2001) 28:780–785.
- LAKSHMINARAYANAN S, WALSH S, MOHANRAJ M, ROTHFIELD N: Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J. RheumatoL (2001) 28:102–108.
- LEVY RA., VILELA VS, CATALDO MJ et al.: Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus (2001) 10:401–404.
- BARDANA EJ JR, PORTER GA, PIROFSKY B, GOURLEY RT, BAYRAKCI C: Azathioprine in steroid-insensitive nephropathy. Am. J. Med. (1970) 49: 789–800.
- DRINKARD JP, STANLEY TM, DORNFELD L et al.: Azathioprine and prednisone in the treatment of adults with lupus nephritis. Clinical, histological, and immunological changes with therapy. Medicine (Baltimore) (1970) 49:411–432.
- EL HACHMI M, JADOUL M, LEFEBVRE C, DEPRESSEUX G, HOUSSIAU FA: Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus (2003) 12:692–696.
- CHAN TM, LI FK, HAO WK et el.: Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus (1999) 8:545–551.
- CONTRERAS G, PARDO V, LECLERCQ B et al.: Sequential therapies for proliferative lupus nephritis. N Engl J. Med. (2004) 350: 971–980.
- MOK CC, HO CT, CHAN KW, LAU CS, WONG RW: Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum. (2002) 46:1003–1013.
- ABU-SHAKRA M, SHOENFELD Y: Azathioprine therapy for patients with systemic lupus erythematosus. Lupus (2001) 10:152–153.
- SATO El: Methotrexate therapy in systemiclupus erythematosus. Lupus (2001) 10:162–164.
- REMER CF, WEISMAN MH, WALLACE DJ: Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus (2001) 10:480–483.
- HU W, LIU Z, SHEN S et al.: Cyclosporine A in treatment of membranous lupus nephropathy. Chin. Med. J. (2003) 116:1827–1830.
- DAMMACCO F, DELLA CASA A et al.: Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. Int. J. Clin. Lab. Res. (2000) 30:67–73.
- STEINBERG AD, KALTREIDE RHB, STAPLES PJ, GOETZL EJ, TALAL N, DECKER JL: Cyclophosphamide in lupus nephritis: a controlled trial. Ann. Intern. Med. (1971) 75:165–171.
- HOUSSIAU FA, VASCONCELOS C, D'CRUZ D, et al.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. (2002) 46:2121–2131.
- BROOK CG, EVANS PR: Psychosis in systemic lupus erythematosus (SLE) and the response to cyclophosphamide. Proc. R. Soc. Med. (1969) 62:912.
- FLANC RS, ROBERTS MA, STRIPPOLI GF, CHADBAN SJ, KERR PG, ATKINS RC: Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am. J. Kidney Dis. (2004) 43:197–208.
- MILLER JJ 3RD, -WILLIAMS GF, LEISSRING JC: Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. Am. J. Med. (1971) 50:530–535.
- WECHSLER B, HUONG DU LT, PIETTE JC: Is there a role for antithrombotic therapy in the prevention of pregnancy loss? Haemostasis (1999) 29:S1:112–20.
- MERRILL JT: Regulation of the vasculature: clues from lupus. Curr .0pin. RheumatoL 2002) 14:504–509.
- FABBRI P, CARDINALI C, GIOMI B, CAPRONI M: Cutaneous lupus erythematosus: diagnosis and management. Am. J. Clin. DermatoL (2003) 4:449–465.
- TRAYNOR AE, SCHROEDER J, ROSA RM, et al.: Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a Phase I study. Lancet (2000) 356:701–707.
- HASHIMOTO N, IWASAKI T, SEKIGUCHI M et al.: Autologous hematopoietic stem cell transplantation for refractory antiphospholipid syndrome causing myocardial necrosis. H. Bone Marrow Transplant (2004) 33:863–866.
- KANG I, PARK SH: Infectious complications in SLE after immunosuppressive therapies. Curr. Opin. RheumatoL (2003) 15:528–534.
- BARR RG, SELIGER S, APPEL GB et al.: Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ ethnicity. NephroL Dial. Transplant (2003) 18:2039–2046.
- CORTES-HERNANDEZ J, ORDI-ROS J,LABRADOR M et al.: Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus (2003) 12:287–296.
- ISENBERG D, LECKIE MJ: Biological treatments for systemic lupus erythematosus. Scand. j RheumatoL (2002) 31:187–191.
- BOGDANOVIC R, NIKOLIC V, PASIC S et al.: Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr. NephroL (2004) 19:36–44.
- ROSENWALD M: No favorite in race totreat lupus the Washington Post (2004) Monday, September 6:E01.
- ARBUCKLE MR, REICHLIN M, HARLEY JB, JAMES JA: Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus. Scand. j ImmunoL (1999) 50:447–455.
- JAMES JA, HARLEY JB: A model of peptide-induced lupus autoimmune B cell epitope spreading is strain specific and is not H-2 restricted in mice. J. ImmunoL (1998) 160:502–508.
- KIM SJ, GERSHOV D, MAX, BROT N, ELKON KB: Opsonization of apoptotic cells and its effect on macrophage and T cell immune responses. Ann. NY Acad. Sci. (2003) 987:68–78.
- RAVIRAJAN CT, PITTONI V, ISENBERG DA: Apoptosis in human autoimmune diseases. Int. Rev. ImmunoL (1999) 18:563-589. Review of the role of apoptosis in autoimmunity with fundamental implications for SLE.
- GRODZICKY T, ELKON KB: Apoptosis:a case where too much or too little can lead to autoimmunity. Mt. Sinai. J. Med. (2002) 69:208–219.
- BAUMLER C, KIM GO, ELKON KB: Growth regulation of activated lymphocytes: defects in homeostasis lead to autoimmunity and/or lymphoma. Rev. Immunogenet. (2000) 2:283–290.
- KAY MM, GOODMAN J: Immunoregulation of cellular lifespan: physiologic autoantibodies and their peptide antigens. Cell MoL Biol. (2003) 49:217–243.
- GARDNER-THORPE J, ITO H, ASHLEY SW, WHANG EE: Autoantibody-mediated inhibition of pancreatic cancer cell growth in an athymic (nude) mouse model. Pancreas (2003) 27:180–189.
- STAFFORD HA, ANDERSON CJ, REICHLIN M: Unmasking of anti-ribosomal P autoantibodies in healthy individuals./ ImmunoL (1995) 155:2754-2761. Evidence that autoantibodies are found in healthy people, changing the paradigm for SLE pathogenesis from an aberrant immune response to a disregulated one.
- BOUVET JP, STAHL D, ROSE S, QUAN CP, KAZATCHKINE MD, KAVERI SV: Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents. J. Autoimmun. (2001) 16:163–172.
- MERRILL JT: Dehydroepiandrosterone, asex steroid metabolite in development for systemic lupus erythematosus. Expert Opin. Investig. Drugs (2003) 12:1017–1025.
- PETRI MA, LAHITA RG, VAN VOLLENHOVEN RF et al.: Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. (2002) 46:1820–1829.
- CHANG DM, LAN JL, LIN HY LUO SF: Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:2924-2927. 63
- DING L, ZHAO M, ZOU W, LIU Y, WANG H: Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study. Lupus (2004) 13:113–118.
- LI L, WANG H, UN S: Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: a multicenter clinical trial in China. Zhonghua Nei Ke Zei Zhi (2002) 41:476-479 (abstract only: paper not available).
- CONTRERAS G, PARDO V, LECLERCQ B et al.: Sequential therapies for proliferative lupus nephritis. N EngL Med. (2004) 350:971–980.
- •Evidence for alternative treatments to cydophosphamide in lupus nephritis.
- HARZALLAH K, BADID C, FOUQUE D, LEFRANCOIS N, TOURAINE JL, LAVILLE M: Efficacy of mycophenolate mofetil on recurrent glomerulonephritis after renal transplantation. Clin. NephroL (2003) 59:212–216.
- ZHAO M, CHEN X, CHEN Y et el.: Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome. Nephrology (2003) 8:2–10.
- CHAN TM, LI FK, TANG CS et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N EngL J. Med. (2000) 343:1156–1163.
- MERRILL JT: UP 1082: a toleragen for Hughes syndrome. Lupus (2004) 13:335–338.
- WEISMAN MH, BLUESTEIN HG, BERNER CM, DE HAAN HA: Reduction in circulating dsDNA antibody titer after administration of UP 394.1 RheumatoL (1997) 24:314–318.
- •Evidence for a biological effect of Riquent.
- WALLACE DJ, TUMLIN JA: UP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus.Lupus (2004) 13:323–327.
- ALARCON-SEGOVIA D, TUMLIN JA, FURIE RA et al.: UP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. (2003) 48:442–454.
- SPERTINI F, LEIMGRUBER A, MOREL B et al.: Idiotypic vaccination with a murine anti-dsDNA antibody: Phase I study in patients with nonactive systemic lupus erythematosus with nephritis. RheumatoL (1999) 26:2602–2608.
- WAISMAN A, RUIZ PJ, ISRAELI E et al.:Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc. Nat. Acad. Sci. (1997) 94(9):4620–4625.
- •Evidence from a murine model supporting the potential use of CR1 peptide in lupus-like disease.
- DAYAB M, SEGAL R, STHOEGER Z et al: J. Clin. ImmunoL (2000) 20:187–192.
- GRAMMER AC, SLOTA R, FISCHER R et al.: Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J. Clin. Invest. (2003) 112:1506–1520.
- HARIGAI M, HARA M, FUKASAWA C et al.: Responsiveness of peripheral blood B cells to re-combinant CD40 ligand in patients with systemic lupus erythematosus. Lupus (1999) 8:227–233.
- UHM WS, NA K, SONG GW et al.: Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (2003) 42(8):935–938.
- KUROIWA T, SCHLIMGEN R, ILLEI GG, BOUMPAS DT: Monocyte response to Thl stimulation and effector function toward human mesangial cells are not impaired in patients with lupus nephritis. Clin. ImmunoL (2003) 106:65–72.
- KATO K, SANTANA-SAHAGUN E, RASSENTI LZ et al.: The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J. Clin. Invest. (1999) 104:947–955.
- HIGUCHI T, AIBAY, NOMURA T et al.: Cutting edge: ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J. ImmunoL (2002) 168:9–12.
- QUEZADA SA, ECKERT M, ADEYI OA, SCHNED AR, NOELLE RJ, BURNS CM: Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis. Rheum. (2003) 48:2541–2554.
- KAIRAITIS L, WANG Y, ZHENG L, TAY YC, WANG Y, HARRIS DC: Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease. Kidney Int. (2003) 64:1265–1272.
- WANG X, HUANG W, SCHIFFER LE, MIHARA M, AKKERMAN A, HIROMATSU K, DAVIDSON A: Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum. (2003) 48:495–506.
- KALLED SL, CUTLER AH, BURKLY LC: Apoptosis and altered dendritic cell homeostasis in lupus nephritis are limited by anti-CD154 treatment. J. ImmunoL (2001) 167:1740–1747.
- BRAMS P, BLACK A, PADLAN EA et al.: A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation. Int. ImmunopharmacoL (2001) 1:277–294.
- HUANG W, SINHA J, NEWMAN J et al.: The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. (2002) 46:1554–1562.
- DAVIS JC JR, TOTORITIS MC, ROSENBERG J, SKLENAR TA, WOFSY D: Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. j RheumatoL (2001) 28:95–101.
- KALUNIAN KC, DAVIS JC JR, MERRILL JT, TOTORITIS MC, WOFSY D: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:3251–3258.
- BOUMPAS DT, FURIE R, MANZI S et al.: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis Arthritis Rheum. (2003) 48:719-727.
- STOHL W, METYAS S, TAN SM et al.: B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. (2003) 48:3475–3486.
- STOHL W: SUE-systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res. Ther. (2003) 5:136–138.
- KAWASAKI A, TSUCHIYA N, FUKAZAWA T, HASHIMOTO H, TOKUNAGA K: Analysis on the association of human BUYS (BAFF, 64 TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun. (2002) 3:424–429.
- ROSCHKE V, SOSNOVTSEVA S, WARD CD et al.: BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. Immunol (2002) 169:4314–4321.
- SESHASAYEE D, VALDEZ P, YAN M, DIXIT VM, TUMAS D, GREWAL IS: Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity (2003) 18:279–288.
- BAKER KP, EDWARDS BM, MAIN SH et al.: Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. (2003) 483:253–265.
- •Characterisation of LymphoStat-B.
- LEANDRO MJ, EDWARDS JC, CAMBRIDGE G, EHRENSTEIN MR, ISENBERG DA: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. (2002) 46(10):2673–2677.
- ANOLIK JH, CAMPBELL D, FELGAR RE, et al.: The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. (2003) 48:455–459.
- WEIDE R, HEYMANNS J, PANDOR FA, KOPPLER H: Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus (2003) 12:779–782.
- ANOLIK J, SANZ I, LOONEY RJ: B cell depletion therapy in systemic lupus erythematosus. Curr. Rheumatol Rep. (2003) 5:350–356.
- LOONEY RJ, ANOLIK JH, CAMPBELL D et al.: B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II does-escalation trial of rituximab. Arthritis Rheum. (2002) 50: 2580–2589.
- •Phase I/II study of rituximab in SLE.
- KNEITZ C, WILHELM M, TONY HP: Effective B cell depletion with rituximab in the treatment of autoimmune diseases. immunobio/ogy (2002) 206:519–527.
- SHANAFELT TD, MADUEME HL, WOLF RC, TEFFERI A: Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo. Clin. Proc. (2003) 78:1340–1346.
- ZAJA F, VIANELLI N SPEROTTO A, DE VITA S, et al.: B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica (2003) 88:538–546.
- CATE R SMIERS FJ, BREDIUS RG, LANKESTER AC, et al.: Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus Rheumatology (2004) 43:244.
- SAITO K, NAWATA M, NAKAYAMADA S, TOKUNAGA M, TSUKADA J, TANAKA Y: Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus (2003) 12:798–800.
- FRA GP, AVANZI GC, BARTOLI E: Remission of refractory lupus nephritis with a protocol including rituximab. Lupus (2003) 12:783–787.
- GLADMAN DD: Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus. Wellesley Hospital, Toronto, Ontario, Canada. Curr. Opin. Rheumatol (1994) 6(5):487–492.
- GLADMAN DD, GOLDSMITH CH, UROWITZ MB et al.: Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J. Rheumatol (1994) 21: 1468–1471.
- HAY EM, BACON PA, GORDON C et al.: The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q. J. Med. (1993) 86:447–458.
- ••Description and study of the BILAGinstrument for measuring disease activity in SLE.
- GLADMAN DD, GOLDSMITH CH, UROWITZ MB et al.: Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J. Rheumatol (1992) 19:608–611.
- BENCIVELLI W, VITALI C, ISENBERG DA et al.: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Clin. Exp. Rheumatol (1992) 10:549–554.
- WARD MM, MARX AS, BARRY NN: Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. Medical Service, VA Palo Alto Health Care System, CA 94304, USA. J. Rheumatol (2000) 27:664–670.
- CORZILLIUS M, FORTIN P, STUCKI G: Responsiveness and sensitivity to change of SLE disease activity measures. Lupus (1999) 8:655–659.
Websites
- http://www.ajmc.com/Article. CLARKE A, The economic impact of SLE Am. J. of Managed Care (2001).
- http://www.lupus.org/education/stats.html Statistics about Lupus. Lupus Foundation of America, Inc.
- ••Some data regarding the economic impactof SLE can be derived from these surveys.
- http://www.bio.com/store/ product.jhtml?id=prod580004. Theta Reports Autoimmune Disease Therapeutics Worldwide: Markets & Developments.
- http://www.genelabs.com/development/ prestaraLupus.html. Genelabs Technologies website.
- http://www.aspreva.com/ products_in_development.html. Aspreva website.
- http://www.roche.com/med-cor- 192003-10-22b. Roche website.
- http://www.ljpc.com/ product_research_thromb.html.La Jolla Pharmaceuticals website.
- http://www.tevapharm.com/research/ products_np.asp. Teva website.
- http://www.hgsi.com/products/index.html. Human Genome Sciences website.
- http://www.gene.com/gene/pipeline/status-immunology/rituxan/. Genentech website.